重组人脑利钠肽治疗老年射血分数降低心力衰竭患者的临床效果

Recombinant Human Brain Natriuretic Peptide in the Treatment of Heart Failure with Reduced Ejection Fraction in Elderly Patients

目的观察重组人脑利钠肽治疗老年射血分数降低心力衰竭(HFrEF)患者的临床效果。方法选取2019年6月至2020年6月天津市红桥医院收治的70例老年HFrEF患者为研究对象,随机分为对照组和试验组,各35例。对照组给予常规治疗,试验组在对照组基础上加用重组人脑利钠肽治疗,治疗7 d后,比较两组的治疗效果、N末端B型利钠肽原(NT-proBNP)水平及左室射血分数。结果治疗后,试验组总有效率高于对照组,差异有统计学意义(P<0.05);试验组NT-proBNP水平低于对照组,左室射血分数高于对照组,差异均有统计学意义(P<0.05)。结论应用重组人脑利钠肽治疗老年HFrEF患者,可明显改善患者的心功能。

Objective To observe the efficacy of recombinant human brain natriuretic peptide in the treatment of heart failure with reduced ejection fraction in elderly patients.Methods Select 70 elderly patients with heart failure with reduced ejection fraction(HFrEF)admitted to the hospital from June 2019 to June 2020 as the research objects,and randomly divide them into a control group and an observation group with 35 cases in each.The control group was given oxygen,diuretics and vasodilators and other anti-heart failure treatments.The research was given recombinant human brain natriuretic peptide in addition to basic treatment.After one week of treatment,the two groups were observed to observe the indicators of cardiac function,serum NT-proBNP,left ventricular ejection fraction.Results The improvement of cardiac function,serum NT-proBNP,left ventricular ejection fraction of the two groups were improved compared with before treatment,the improvement of cardiac function,serum NT-proBNP,left indexes such as ventricular ejection fraction of research group were better than those of the control group,and the differences were statistically significant(P<0.05).Conclusion Recombinant human brain natriuretic peptide has a very good effect in the treatment of heart failure with reduced ejection fraction in elderly patients.